

Investment Objective

The investment objective of the Kieger UCITS Fund - Kieger Impact Healthcare Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals. The fund is actively managed by the Investment Manager.

SFDR classification: Article 9

The fund has sustainable investment as its objective.

Key Information

General Information

ISIN	LU2207278073
BLOOMBERG	KGIHAUA LX
Fund Inception	01/10/2020
Share Class Inception	01/10/2020
Total Assets	USD 80.9m
Fund Currency	USD
Domicile	Luxembourg
Regulatory Status	SICAV
Legal Structure	UCITS
Dealing Frequency	Daily (CET 12pm)
Settlement	T+2
Distribution Policy	Accumulating

Service Providers

Management Company	FundRock Management Co. SA
Investment Manager	Kieger AG
Custodian Bank/ Administrator	Northern Trust Global Services SE
Auditor	Ernst & Young SA

Fund Management

Maria Specogna (Co-Mgr)
Raphael Oesch (Co-Mgr)

Portfolio Statistics (3-Year Annualised)

	Fund
Volatility	23.06%
Sharpe Ratio	-0.76
Tracking Error	-
Information Ratio	
Beta	1.38
Active Share	89.54%

Largest Holdings (%)

BioNTech SE	3.9%
Radnet Inc	3.4%
Inspire Medical Systems Inc	3.4%
Natera Inc	3.4%
Revvity Inc	3.4%
Ambu A/S	3.4%
Amplifon Spa	3.3%
ResMed Inc	3.3%
Ionis Pharmaceuticals	3.2%
Hikma Pharmaceuticals PLC	3.2%
Total Top 10 - out of 35	33.9%


Performance (%)

Performance data are net of management fees, but do not reflect sales charges or the effect of taxes.



Past performance is no indication of current or future performance.

	1 Month	3 Months	YTD	1 Yr	3 Yrs	5 Yrs
USD A Class Accumulating	-5.38%	-4.87%	-8.25%	10.35%	-11.85%	-



Past performance is no indication of current or future performance.

Manager Commentary

Market review: October was a tough month for healthcare amidst a rocky macro picture. In the US markets, it was the worse month year-to-date on a relative basis, globally, the second worse. A large part of this underperformance can be attributed to huge moves in specific sub-sectors of the healthcare space, as explained below. The managed care companies with exposure to governmental health insurance programs were the largest contributors to this month's sector underperformance. There are 3 reasons for this: First is the sustained high rate of healthcare utilization in the US for Medicare patients, now for the 7th quarter in a row. Second, upcoming changes to reimbursement laws have led to large increases in drug volumes for seniors. Third, with the redetermination of eligibility of Medicaid coverage - which was paused during COVID - the acuity mix of the population has shifted without being reflected in the state insurance rates. Overall, these effects mean stronger demand for healthcare, which is positive for other companies. The Life Science Tools & Services space was also under severe pressure, in large part due to weakness in contract research organisation (CRO) names. These companies are highly dependent on small but also large biotech and pharmaceutical companies outsourcing a part of their clinical trial operation to them. Despite the relative pick-up in the Biotech funding environment over the past 12 months, this has so far not been translating into increased CRO business. In addition, the book of large-cap business also seems to be slowing. Overall, it seems the shifting end market demand is still misunderstood by markets and companies.


Portfolio changes: We initiated positions in Gilead, Hologic and Novo Nordisk and we exited Allogene, Alto, Annovis, Atai, Bioarctic, Caribou, Cassava, Compass, Cybin, Esperion, Immune, Ionis, Mind Medicine, Organon, Quanterix and Sage.

Performance review: The largest contributors were Penumbra (+59 bps / Completed the THUNDER IDE clinical study enrollment for patients with acute ischemic stroke. Later, Penumbra beat Q3 expectations), Intra-Cellular (+51 bps / Solid Q3 results, driven by continued strong performance of CAPLYTA) and Esperion (+31 bps / Esperion's partner, Daiichi Sankyo, reported promising results from MILOS German cohort, showing an increase in LDL-C goal achievement). The largest detractors were Tandem (-89 bps / General worries of slowing diabetes device market going forward with limited company specific news flow), Hypera (-71 bps / On October 18th, Hypera announced a working capital improvement process and discontinued the FY 2024 guidance. Additionally, the company disclosed Q3 figures well below consensus forecasts. Following the announcement, Hypera received an offer from EMS (Brazil's largest pharma firm), proposing a business combination. Later in the month, Hypera rejected the offer and the stock fell) and Centene (-59 bps / Came under pressure after peers commented on ongoing acuity/ rate mismatch in Medicaid reimbursement. Reasonable good Q3 results at the end of the month were only partially able to compensate).


ESG: Firms in the portfolio did not report any material ESG issues in October.

as of 31/10/2024


Regional Exposure (%)



Sector Exposure (%)




Market Cap Breakdown (%)



Large = >15bn, Mid = 5-15bn, Small = <5bn

Impact Theme Allocation (%)



Share Class Information

Share Class	ISIN	Bloomberg	Investment Management Fee	TER - as of Dec 2023	Minimum Investment	NAV
USD A Class Accumulating	LU2207278073	KGIHAAUA LX	1.00%	1.21%	500,000	80.04
CHF A (H) Class Acc	LU2207278404	KGIHAAHC LX	1.00%	1.27%	500,000	82.33
USD B Class Accumulating	LU2488093613	KGIHAAAU LX	1.00%	1.22%	5,000	91.52
EUR B Class Accumulating	LU2488093456	KGIHAAAE LX	1.00%	1.22%	5,000	90.04
CHF B Class Accumulating	LU2488093530	KGIHAAAC LX	1.00%	1.22%	5,000	86.1
USD R Class Accumulating	LU2207278669	KGIHAAUA LX	2.00%	2.22%	2,000	88.73

Disclaimer

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

The information in this document is intended exclusively for professional clients within the meaning of Annex II MiFID II. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus.

A summary of the investor rights is available in English at

<https://kieger.com/regulatory-disclosures>.

Further information about the sustainability-related aspects of the Fund is available at

<https://kieger.com/regulatory-disclosures>

The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

Information for Swiss Investors:

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Maintower, Thurgauerstrasse 36/38, CH-8050 Zurich, Switzerland, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

Information for German Investors:

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Line-Eid-Strasse 6, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email facilityagent@acolin.com, or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

Information for Austrian Investors: The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email foreignfunds0540@erstebank.at

Marketing in the European Union:

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II" as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his home country Luxembourg. Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be copied or used for other purposes, nor may the content of the document be forwarded to third parties.